Zydus Lifesciences Limited — Updates, 12-11-2024: Press Release

Zydus Lifesciences Ltd. has reported strong financial results for the quarter and half-year ended September 30, 2024, with significant growth across its operational segments. Q2 revenue from operations reached ₹52,370 million, a 20% increase year-on-year, while EBITDA rose 28% to ₹14,614 million, resulting in an EBITDA margin of 27.9%. Net profit for the quarter was ₹9,112 million, reflecting a 14% year-on-year growth. In the half-year period, operational revenue stood at ₹114,445 million, also up 20%, with net profit increasing by 24% to ₹23,311 million.

The company continues to invest in research and development, with Q2 R&D expenses at ₹4,800 million, representing 9.2% of revenues. The U.S. formulations business performed notably well, achieving ₹24,168 million in revenue, up 30% year-on-year, bolstered by product launches and regulatory approvals. Zydus has strengthened its pipeline and market presence through strategic initiatives, including the recent agreement to acquire Naturell (India) Pvt. Ltd., which enhances its consumer wellness portfolio. Overall, the company maintains a positive outlook, driven by robust performance and strategic growth initiatives.